X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
neurology (42) 42
science & technology (38) 38
alzheimer's disease (36) 36
humans (33) 33
life sciences & biomedicine (29) 29
female (27) 27
male (25) 25
neurosciences & neurology (23) 23
aged (22) 22
neurosciences (21) 21
immunotherapy (19) 19
brain (16) 16
clinical neurology (16) 16
middle aged (16) 16
alzheimer disease - drug therapy (14) 14
magnetic resonance imaging (12) 12
aged, 80 and over (11) 11
clinical trials (11) 11
antibodies, monoclonal, humanized - therapeutic use (9) 9
treatment outcome (9) 9
alzheimer disease - genetics (8) 8
alzheimers disease (8) 8
alzheimer disease (7) 7
alzheimer disease - cerebrospinal fluid (7) 7
alzheimer disease - diagnostic imaging (7) 7
analysis (7) 7
animals (7) 7
biomarkers (7) 7
brain - pathology (7) 7
care and treatment (7) 7
cognition (7) 7
double-blind method (7) 7
longitudinal studies (7) 7
multidisciplinary sciences (7) 7
neuroimaging (7) 7
science & technology - other topics (7) 7
abridged index medicus (6) 6
brain - diagnostic imaging (6) 6
cerebrospinal fluid (6) 6
neurodegenerative diseases (6) 6
neurovetenskaper (6) 6
studies (6) 6
alzheimer disease - metabolism (5) 5
alzheimer disease - pathology (5) 5
amyloid (5) 5
biological markers (5) 5
brain - drug effects (5) 5
brain - metabolism (5) 5
dementia (5) 5
diagnostic imaging (5) 5
medical research (5) 5
medicine, experimental (5) 5
positron emission tomography (5) 5
positron-emission tomography (5) 5
science (5) 5
severity of illness index (5) 5
tau proteins - cerebrospinal fluid (5) 5
united states (5) 5
alzheimer disease - diagnosis (4) 4
alzheimer’s disease (4) 4
amyloid beta-protein (4) 4
antibodies (4) 4
antibodies, monoclonal, humanized - administration & dosage (4) 4
apolipoproteins e - genetics (4) 4
bapineuzumab (4) 4
biomarker (4) 4
biomarkers - cerebrospinal fluid (4) 4
cognitive ability (4) 4
dose-response relationship, drug (4) 4
drug therapy (4) 4
edema (4) 4
electricity (4) 4
genetic aspects (4) 4
genetics (4) 4
monoclonal antibodies (4) 4
neuroimaging - methods (4) 4
oncology (4) 4
patients (4) 4
research (4) 4
tau (4) 4
tau protein (4) 4
adult (3) 3
aging (3) 3
amyloid beta-peptides (3) 3
amyloid beta-peptides - blood (3) 3
amyloid beta-peptides - cerebrospinal fluid (3) 3
amyloid beta-peptides - metabolism (3) 3
amyloidosis (3) 3
animal structures (3) 3
antibodies, monoclonal, humanized - adverse effects (3) 3
basic electric elements (3) 3
brain - physiopathology (3) 3
cognitive neuroscience (3) 3
cohort studies (3) 3
diagnosis (3) 3
disease models, animal (3) 3
genetic variation (3) 3
genome-wide association study (3) 3
health aspects (3) 3
immunologic factors - therapeutic use (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 01/2014, Volume 370, Issue 4, pp. 322 - 333
In two phase 3 trials in patients with Alzheimer's disease, bapineuzumab, a humanized anti–amyloid-beta monoclonal antibody, did not improve clinical outcomes.... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Phosphorylation | Humans | Middle Aged | Male | Positron-Emission Tomography | Treatment Failure | Aged, 80 and over | Amyloid beta-Peptides - cerebrospinal fluid | Female | Severity of Illness Index | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Biomarkers - analysis | Alzheimer Disease - drug therapy | tau Proteins - cerebrospinal fluid | Alzheimer Disease - cerebrospinal fluid | Cognition - drug effects | Neuropsychological Tests | Amyloid beta-Peptides - antagonists & inhibitors | Apolipoproteins E - genetics | Intention to Treat Analysis | Amyloid beta-Peptides - analysis | Brain - pathology | Aged | Biomarkers - cerebrospinal fluid | Edema - chemically induced | Alzheimer Disease - genetics | Monoclonal antibodies | Product development | Research | Drug therapy | Alzheimer's disease | Health aspects | Edema | Nuclear magnetic resonance--NMR | Intravenous administration | Neurodegenerative diseases | Cognitive ability | Clinical trials | Cerebrospinal fluid | Patients | Studies | Tau protein | Apolipoprotein E | Immunotherapy | Alleles | Dementia disorders | Alzheimers disease | Index Medicus | Abridged Index Medicus | Brain | Neurosciences | pathology | Biological Markers | Antibodies | Cognition | tau Proteins | 80 and over | genetics | Amyloid beta-Peptides | Apolipoproteins E | Monoclonal | Neurovetenskaper | drug therapy | chemically induced | Humanized | drug effects | Alzheimer Disease | analysis | antagonists & inhibitors | cerebrospinal fluid | adverse effects | therapeutic use
Journal Article
Lancet neurology, ISSN 1474-4422, 2012, Volume 11, Issue 3, pp. 241 - 249
Journal Article
Alzheimer's & dementia, ISSN 1552-5260, 04/2018, Volume 14, Issue 4, pp. 535 - 562
Journal Article
International journal of alzheimer's disease, ISSN 2090-8024, 1/2012, Volume 2012, pp. 628070 - 14
As the societal and economic burdens of Alzheimer's disease (AD) continue to mount, so does the need for therapies that slow the progression of the illness.... 
Review
Journal Article
Journal of Neurology, Neurosurgery & Psychiatry, ISSN 0022-3050, 01/2016, Volume 87, Issue 1, pp. 106 - 112
BackgroundAmyloid-related imaging abnormalities due to haemosiderin deposition (ARIA-H) occur in patients with mild to moderate dementia due to Alzheimer's...